AstraZeneca Tops Profit Estimates, Maintains Full-Year Guidance

• First-quarter revenue rose 8% to $15.29 billion with oncology sales up 16% and rare disease unit sales up 15%
• AstraZeneca targets over 20 new drug launches by 2030, with three potential U.S. approvals expected in 2025 for high blood pressure, breast cancer, and autoimmune disease treatments
• The company maintains expectations for low double-digit percentage growth in core earnings in 2026 and mid-to-high single-digit revenue growth despite navigating U.S. 'most-favored-nation' pricing policy challenges

Summary

Key Financial Performance:

AstraZeneca exceeded first-quarter profit expectations with revenue rising 8% to $15.29 billion and core earnings of $2.58 per share for the quarter ended March 31. Oncology sales grew 16% and rare disease unit sales increased 15%, while U.S. revenue advanced 10% and China sales rose 2%.

Strategic Outlook:

The company maintained its 2026 guidance, projecting low double-digit core earnings growth and mid-to-high single-digit revenue growth at constant currencies. CEO Pascal Soriot reaffirmed the ambitious $80 billion annual revenue target for 2030, with analysts forecasting 7.2% sales growth and 11.2% profit growth in 2026.

Pipeline and Expansion:

AstraZeneca is preparing to launch three drugs pending U.S. regulatory approval this year: baxdrostat (high blood pressure), camizestrant (breast cancer), and gefurulimab (chronic autoimmune disease). The company targets over 20 new drug launches by 2030 to offset pricing pressures and patent losses.

Market Challenges:

The drugmaker faces headwinds from U.S. "most-favored-nation" pricing policies linking American drug prices to lower international costs, prompting companies to seek higher overseas prices or delay launches. Soriot warned that Europe risks becoming merely a "sales office" as it lags behind the U.S. and China in life sciences competitiveness.

Market Reaction:

AstraZeneca shares rose marginally by 0.2% in early London trading while the FTSE 100 fell 0.6%. Analysts noted the muted response suggests the company's strong momentum was already priced into the stock, which has significantly outperformed both the FTSE 100 and STOXX 600 under Soriot's leadership.